"Designing Growth Strategies is in our DNA"

Middle East & Africa Human Insulin Market Size, Share & COVID-19 Impact Analysis, By Type (Analog Insulin, and Traditional Insulin), By Diabetes Type (Diabetes 1, and Diabetes 2), By Distribution Channel (Hospital Pharmacy, and Retail & Online Pharmacy), and Regional Forecast, 2023-2030

Last Updated: December 01, 2025 | Format: PDF | Report ID: FBI107470

 

We will customize the report to meet your research goals, helping you gain a competitive edge, and make informed decisions.

  1. Introduction
    1. Research Scope
    2. Market Segmentation
    3. Research Methodology
    4. Definitions and Assumptions
  2. Executive Summary
  3. Market Dynamics
    1. Market Drivers
    2. Market Restraints
    3. Market Opportunities
    4. Market Trends
  4. Key Insights
    1. Pipeline Analysis, By Key Players
    2. Pricing Analysis, By Key Countries, 2022
    3. Prevalence of Diabetes, By Key Countries, 2022
    4. Brand Analysis – By Key Countries
    5. Key Market Strategies, By Key Players
    6. Overview of Regulatory Scenario – For Key Countries/Sub-regions
    7. Impact of COVID-19 on the Market
  5. Middle East & Africa Human Insulin Market Analysis, Insights and Forecast, 2019-2030
    1. Market Analysis, Insights and Forecast – By Type
      1. Analogue Insulin
        1. Long-acting
        2. Fast-acting
        3. Premix
      2. Traditional Human Insulin
        1. Long-acting
        2. Short-acting
        3. Fast-acting
        4. Premix
    2. Market Analysis, Insights and Forecast – By Diabetes Type
      1. Diabetes Type 1
      2. Diabetes Type 2
    3. Market Analysis, Insights and Forecast – By Distribution Channel
      1. Hospital Pharmacies
      2. Retail & Online Pharmacies
  6. Market Analysis, Insights and Forecast – By Country/Sub-region
      1. GCC
        1. By Diabetes Type
      2. South Africa
        1. By Diabetes Type
      3. Rest of Middle East & Africa
        1. By Diabetes Type
  7. Competitive Analysis
    1. Middle East & Africa Market Share Analysis (2022)
    2. Company Profiles (Overview, Product, SWOT Analysis, Recent Developments, Strategies, financials (Based on Availability))
      1. Novo Nordisk A/S
        1. Overview,
        2. Product,
        3. SWOT Analysis,
        4. Recent Developments,
        5. Strategies,
        6. financials (Based on Availability)
      2. Eli Lilly and Company
        1. Overview,
        2. Product,
        3. SWOT Analysis,
        4. Recent Developments,
        5. Strategies,
        6. financials (Based on Availability)
      3. Sanofi
        1. Overview,
        2. Product,
        3. SWOT Analysis,
        4. Recent Developments,
        5. Strategies,
        6. financials (Based on Availability)
      4. Julphar
        1. Overview,
        2. Product,
        3. SWOT Analysis,
        4. Recent Developments,
        5. Strategies,
        6. financials (Based on Availability)
      5. Biocon 
        1. Overview,
        2. Product,
        3. SWOT Analysis,
        4. Recent Developments,
        5. Strategies,
        6. financials (Based on Availability)
      6. BIOTON S.A.
        1. Overview,
        2. Product,
        3. SWOT Analysis,
        4. Recent Developments,
        5. Strategies,
        6. financials (Based on Availability)
      7. Lupin
        1. Overview,
        2. Product,
        3. SWOT Analysis,
        4. Recent Developments,
        5. Strategies,
        6. financials (Based on Availability)
      8. Exir
        1. Overview,
        2. Product,
        3. SWOT Analysis,
        4. Recent Developments,
        5. Strategies,
        6. financials (Based on Availability)
      9. VACSERA
        1. Overview,
        2. Product,
        3. SWOT Analysis,
        4. Recent Developments,
        5. Strategies,
        6. financials (Based on Availability)
      10. SEDICO
        1. Overview,
        2. Product,
        3. SWOT Analysis,
        4. Recent Developments,
        5. Strategies,
        6. financials (Based on Availability)
      11. Other Prominent Players
        1. Overview,
        2. Product,
        3. SWOT Analysis,
        4. Recent Developments,
        5. Strategies,
        6. financials (Based on Availability)
  1. Introduction
    1. Research Scope
    2. Market Segmentation
    3. Research Methodology
    4. Definitions and Assumptions
  2. Executive Summary
  3. Market Dynamics
    1. Market Drivers
    2. Market Restraints
    3. Market Opportunities
    4. Market Trends
  4. Key Insights
    1. Pipeline Analysis, By Key Players
    2. Pricing Analysis, By Key Countries, 2022
    3. Prevalence of Diabetes, By Key Countries, 2022
    4. Brand Analysis – By Key Countries
    5. Key Market Strategies, By Key Players
    6. Overview of Regulatory Scenario – For Key Countries/Sub-regions
    7. Impact of COVID-19 on the Market
  5. Middle East & Africa Human Insulin Market Analysis, Insights and Forecast, 2019-2030
    1. Market Analysis, Insights and Forecast – By Type
      1. Analogue Insulin
        1. Long-acting
        2. Fast-acting
        3. Premix
      2. Traditional Human Insulin
        1. Long-acting
        2. Short-acting
        3. Fast-acting
        4. Premix
    2. Market Analysis, Insights and Forecast – By Diabetes Type
      1. Diabetes Type 1
      2. Diabetes Type 2
    3. Market Analysis, Insights and Forecast – By Distribution Channel
      1. Hospital Pharmacies
      2. Retail & Online Pharmacies
  6. Market Analysis, Insights and Forecast – By Country/Sub-region
      1. GCC
        1. By Diabetes Type
      2. South Africa
        1. By Diabetes Type
      3. Rest of Middle East & Africa
        1. By Diabetes Type
  7. Competitive Analysis
    1. Middle East & Africa Market Share Analysis (2022)
    2. Company Profiles (Overview, Product, SWOT Analysis, Recent Developments, Strategies, financials (Based on Availability))
      1. Novo Nordisk A/S
        1. Overview,
        2. Product,
        3. SWOT Analysis,
        4. Recent Developments,
        5. Strategies,
        6. financials (Based on Availability)
      2. Eli Lilly and Company
        1. Overview,
        2. Product,
        3. SWOT Analysis,
        4. Recent Developments,
        5. Strategies,
        6. financials (Based on Availability)
      3. Sanofi
        1. Overview,
        2. Product,
        3. SWOT Analysis,
        4. Recent Developments,
        5. Strategies,
        6. financials (Based on Availability)
      4. Julphar
        1. Overview,
        2. Product,
        3. SWOT Analysis,
        4. Recent Developments,
        5. Strategies,
        6. financials (Based on Availability)
      5. Biocon 
        1. Overview,
        2. Product,
        3. SWOT Analysis,
        4. Recent Developments,
        5. Strategies,
        6. financials (Based on Availability)
      6. BIOTON S.A.
        1. Overview,
        2. Product,
        3. SWOT Analysis,
        4. Recent Developments,
        5. Strategies,
        6. financials (Based on Availability)
      7. Lupin
        1. Overview,
        2. Product,
        3. SWOT Analysis,
        4. Recent Developments,
        5. Strategies,
        6. financials (Based on Availability)
      8. Exir
        1. Overview,
        2. Product,
        3. SWOT Analysis,
        4. Recent Developments,
        5. Strategies,
        6. financials (Based on Availability)
      9. VACSERA
        1. Overview,
        2. Product,
        3. SWOT Analysis,
        4. Recent Developments,
        5. Strategies,
        6. financials (Based on Availability)
      10. SEDICO
        1. Overview,
        2. Product,
        3. SWOT Analysis,
        4. Recent Developments,
        5. Strategies,
        6. financials (Based on Availability)
      11. Other Prominent Players
        1. Overview,
        2. Product,
        3. SWOT Analysis,
        4. Recent Developments,
        5. Strategies,
        6. financials (Based on Availability)
Read Less

Figure 1:  Middle East & Africa Human Insulin Market Value (USD billion), by Type, 2022 & 2030

Figure 2:  Middle East & Africa Human Insulin Market Value Share (%), by Type, 2022

Figure 3:  Middle East & Africa Human Insulin Market Value (USD billion), by Diabetes Type, 2022 & 2030

Figure 4:  Middle East & Africa Human Insulin Market Value Share (%), by Diabetes Type, 2022

Figure 5:  Middle East & Africa Human Insulin Market Value (USD billion), by Distribution Channel, 2022 & 2030

Figure 6:  Middle East & Africa Human Insulin Market Value Share (%), by Distribution Channel, 2022

Figure 7:  Middle East & Africa Human Insulin Market Value (USD billion), By Country/ Sub-region, 2022 & 2030

Figure 8:  Middle East & Africa Human Insulin Market Value Share (%), By Country/ Sub-region, 2022

Figure 9:  Middle East & Africa Human Insulin Market Share (%), By Company, 2022

Table 1:  Middle East & Africa Human Insulin Market Revenue (USD billion) Forecast, by Type, 2019-2030

Table 2:  Middle East & Africa Human Insulin Market Revenue (USD billion) Forecast, by Diabetes Type, 2019-2030

Table 3:  Middle East & Africa Human Insulin Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2030

Table 4:  Middle East & Africa Human Insulin Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2030

Table 5:  GCC Human Insulin Market Revenue (USD billion) Forecast, By Diabetes Type, 2019-2030

Table 6:  South Africa Human Insulin Market Revenue (USD billion) Forecast, By Diabetes Type, 2019-2030

Table 7:  Rest of Middle East & Africa Human Insulin Market Revenue (USD billion) Forecast, By Diabetes Type, 2019-2030

Middle East & Africa Human Insulin Market
  • 2019-2030
  • 2022
  • 2019-2021
  • 109
Download Free Sample

    man icon
    Mail icon
    Captcha refresh
Growth Advisory Services
    How can we help you uncover new opportunities and scale faster?
Clients
3M
Toshiba
Fresenius
Johnson
Siemens
Abbot
Allergan
American Medical Association
Becton, Dickinson and Company
Bristol-Myers Squibb Company
Henry Schein
Mckesson
Mindray
National Institutes of Health (NIH)
Nihon Kohden
Olympus
Quest Diagnostics
Sanofi
Smith & Nephew
Straumann

Related Reports